Schizophrenia/schizoaffective disorder Mental and Behavioural Disorders Schizophrenia
Conditions
Interventions
Psychiatrists will be randomised to the intervention group (training programme) or control group (no training programme).
Training programme:
The proposed training programme is as follows. Training w
Sponsors
Queen Mary University of London (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Psychiatrists: Higher/advanced psychiatric trainees (ST4-6) working in outpatients or community mental health teams. Doctors in higher psychiatric training (ST4-6) already have basic knowledge and experience in psychiatry gained through core psychiatric training. During higher training they practice without direct supervision and aim to further develop specific competencies including communication skills. Hence, they are at the formative stage of their training, preparing to take up a consultant role in a few years time. We will focus on trainees in this pilot trial, because the effectiveness of an intervention on changing their communicative practice may be higher at this stage of their professional development. Patients: 1. ICD-10 criteria for a diagnosis of schizophrenia or schizoaffective disorder 2. Currently attending outpatients or being cared for by community mental health teams 3. Capable of giving informed consent 4. Aged 18 - 65 years, both females and males
Exclusion criteria
Exclusion criteria: Patients: 1. Organic impairment 2. Require an interpreter
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psychiatrists use of repair will be assessed using the Repair Protocol, which is a standardised and validated measure. | — |
Secondary
| Measure | Time frame |
|---|---|
| Intermediate outcomes: 1. Psychiatrist confidence in communicating with psychotic patients 2. Patient experience of the communication 3. Patient centredness Measured in the first consultation with each relevant patient after the 12 week training period Final outcomes: 4. Patient satisfaction with treatment 5. Therapeutic relationship 6. Treatment adherence and relapse Measured at 6 months follow-up | — |
Countries
United Kingdom
Outcome results
None listed